Biomarkers in infants with prior neonatal brain injury
Official title: Early Biomarkers Study for Prediction of Executive Dysfunction and Cognitive Outcomes Among Infants With Prior Neonatal Brain Injury
Run by University of Wisconsin, Madison · NCT07413900 · Data updated 2026-11-12
This project will test brain activity and development using games, EEG, and parent questionnaires in infants aged 3–24 months with and without prior neonatal brain injury.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 3 Months to 24 Months |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | March 13, 2023 |
| Main results expected | March 15, 2030 |
| Study ends | March 15, 2030 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07413900 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are infants aged 3–24 months and their parent or legal guardian, including those with a neonatal history of HIE, prematurity under 32 weeks, or cerebral palsy, as well as healthy control infants without prior neurological problems, and families able to attend visits at UW–Madison.
✕Probably not a fit
Infants outside the 3–24 month age range, those with exclusionary neurological conditions for the control group, or families unable to travel to the study site are unlikely to benefit directly from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project enrolls child-parent pairs to compare infants with prior perinatal brain injury (including HIE, very preterm birth, or cerebral palsy) to healthy infants. Participants complete in-person developmental games and cognitive assessments at the University of Wisconsin–Madison hospital, undergo an EEG, and parents fill out questionnaires about behavior and home stress. The protocol is noninterventional and focuses on identifying biomarkers and patterns linked to later cognitive development. Results aim to improve understanding of early markers that predict developmental trajectories.
Why it matters
Potential benefit: If successful, the findings could help identify early signs of altered brain development and support earlier referral to therapies or monitoring.
How similar studies have gone: Previous research using EEG and behavioral testing has shown promise for detecting early developmental differences after neonatal brain injury, but definitive clinical biomarkers remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Child-parent dyads will be recruited to the study. * Children 3-24 months with and without a history of a perinatal brain injury (PBI) will be included in this study. * Children with PBIs will include: * Children diagnosed during the neonatal period with hypoxic-ischemic encephalopathy, * Children born at a premature gestational age (born at less than 32 weeks gestational age). * Children diagnosed with cerebral palsy * Healthy control participants meeting inclusion criteria will include: * healthy infants with no prior neurological (brain disorder) history * For all parents: the only research inclusion criteria is to be the parent or legal guardian of a newborn with perinatal brain injury or healthy control participant. Exclusion Criteria: * Healthy infants to be included in the control group will not have: * a prior history of brain injury * a diagnosis of cerebral palsy * a history of a neurological disorder * prior admission to the Neonatal Intensive Care Unit (NICU) * Children with chromosomal abnormalities, genetic syndromes and major congenital malformations will be excluded from both the patient groups and the control group. * Parents will have no exclusionary criteria.
Where it's running
-
University of Wisconsin Madison University Hospital
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Melisa Carrasco McCaul, MD, PhD — University of Wisconsin, Madison
- Study coordinator: Melisa Carrasco McCaul, MD, PhD
- Email: carrascomccaul@neurology.wisc.edu
- Phone: 608-577-2415
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Wireless MicroPremVitals Button Sensor for the NICU
This study tests a tiny wireless sensor system to monitor heart rate, oxygen, and temperature in extremely preterm babies in the NICU to see if it works safely without wires.
-
Caffeine in pregnancy: how the mother and baby handle it during delivery
This study tests how caffeine is processed in pregnant people and how much reaches the baby when given shortly before delivery.
-
Neonatal data and biobank to understand what influences development in very preterm infants
This project will collect clinical information and biological samples to see if early biological, clinical, and environmental factors predict short- and long-term development in infants born before 32 weeks or under 1500 g.
-
PIOMI plus time‑based feeding to help preterm babies start oral feeds and gain weight
We will test whether a specific oral‑motor routine (PIOMI) and a time‑based (chronobiological) feeding approach help preterm infants born at 29–33 weeks begin oral feeding sooner and gain weight better.
-
Home air purifier to support lung recovery in babies born prematurely
This tests whether using an air purifier at home improves breathing and oxygen levels in babies who were born prematurely.
-
Adding azithromycin to ampicillin for late PPROM
This test sees if adding a single dose of azithromycin to the usual ampicillin/amoxicillin treatment helps newborns when membranes break early between 34.0 and 36.6 weeks.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.